Politi Letterio S, Bacigaluppi Marco, Brambilla Elena, Cadioli Marcello, Falini Andrea, Comi Giancarlo, Scotti Giuseppe, Martino Gianvito, Pluchino Stefano
Neuroradiology Unit, Centro Eccellenza Risonanza Magnetica ad Alto Campo, Italy.
Stem Cells. 2007 Oct;25(10):2583-92. doi: 10.1634/stemcells.2007-0037. Epub 2007 Jun 28.
Eliciting the in situ accumulation and persistence patterns of stem cells following transplantation would provide critical insight toward human translation of stem cell-based therapies. To this end, we have developed a strategy to track neural stem/precursor cells (NPCs) in vivo using magnetic resonance (MR) imaging. Initially, we evaluated three different human-grade superparamagnetic iron oxide particles for labeling NPCs and found the optimal labeling to be achieved with Resovist. Next, we carried out in vivo experiments to monitor the accumulation of Resovist-labeled NPCs following i.v. injection in mice with experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis. With a human MR scanner, we were able to visualize transplanted cells as early as 24 hours post-transplantation in up to 80% of the brain demyelinating lesions. Interestingly, continued monitoring of transplanted mice indicated that labeled NPCs were still present 20 days postinjection. Neuropathological analysis confirmed the presence of transplanted NPCs exclusively in inflammatory demyelinating lesions and not in normal-appearing brain areas. Quantification of transplanted cells by means of MR-based ex vivo relaxometry (R2*) showed significantly higher R2* values in focal inflammatory brain lesions from EAE mice transplanted with labeled NPCs as compared with controls. Indeed, sensitive quantification of low numbers of NPCs accumulating into brain inflammatory lesions (33.3-164.4 cells per lesion; r(2) = .998) was also obtained. These studies provide evidence that clinical-grade human MR can be used for noninvasive monitoring and quantification of NPC accumulation in the central nervous system upon systemic cell injection. Disclosure of potential conflicts of interest is found at the end of this article.
探究移植后干细胞的原位积累和持久性模式,将为基于干细胞的疗法向人体转化提供关键见解。为此,我们开发了一种利用磁共振(MR)成像在体内追踪神经干细胞/前体细胞(NPCs)的策略。最初,我们评估了三种不同的人用级超顺磁性氧化铁颗粒对NPCs进行标记,发现使用Resovist可实现最佳标记效果。接下来,我们进行了体内实验,以监测在实验性自身免疫性脑脊髓炎(EAE,多发性硬化症的动物模型)小鼠静脉注射后,Resovist标记的NPCs的积累情况。使用人体MR扫描仪,我们能够在移植后24小时最早在高达80%的脑脱髓鞘病变中可视化移植细胞。有趣的是,对移植小鼠的持续监测表明,标记的NPCs在注射后20天仍存在。神经病理学分析证实,移植的NPCs仅存在于炎性脱髓鞘病变中,而不存在于外观正常的脑区。通过基于MR的离体弛豫测量法(R2*)对移植细胞进行定量分析,结果显示,与对照组相比,移植了标记NPCs的EAE小鼠局灶性炎性脑病变中的R2*值显著更高。事实上,还实现了对积聚在脑炎性病变中的少量NPCs(每个病变33.3 - 164.4个细胞;r(2) = 0.998)进行灵敏定量分析。这些研究提供了证据,表明临床级人体MR可用于全身细胞注射后对中枢神经系统中NPC积累进行无创监测和定量分析。潜在利益冲突的披露见本文末尾。